ATE453669T1 - Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen - Google Patents

Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen

Info

Publication number
ATE453669T1
ATE453669T1 AT03726739T AT03726739T ATE453669T1 AT E453669 T1 ATE453669 T1 AT E453669T1 AT 03726739 T AT03726739 T AT 03726739T AT 03726739 T AT03726739 T AT 03726739T AT E453669 T1 ATE453669 T1 AT E453669T1
Authority
AT
Austria
Prior art keywords
fused
protein
ferritin
applications
polymeric
Prior art date
Application number
AT03726739T
Other languages
English (en)
Inventor
Daniel Carter
Chester Li
Original Assignee
New Century Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Century Pharmaceuticals filed Critical New Century Pharmaceuticals
Application granted granted Critical
Publication of ATE453669T1 publication Critical patent/ATE453669T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03726739T 2002-05-10 2003-05-12 Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen ATE453669T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37914502P 2002-05-10 2002-05-10
PCT/US2003/014617 WO2003094849A2 (en) 2002-05-10 2003-05-12 Ferritin fusion proteins for use in vaccines and other applications

Publications (1)

Publication Number Publication Date
ATE453669T1 true ATE453669T1 (de) 2010-01-15

Family

ID=29420496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726739T ATE453669T1 (de) 2002-05-10 2003-05-12 Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen

Country Status (8)

Country Link
US (2) US7097841B2 (de)
EP (1) EP1504037B1 (de)
CN (2) CN1659187A (de)
AT (1) ATE453669T1 (de)
AU (1) AU2003228962A1 (de)
CA (1) CA2485363C (de)
DE (1) DE60330767D1 (de)
WO (1) WO2003094849A2 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US9089521B2 (en) * 2001-11-01 2015-07-28 Robert H. Broyles Method for regulating production of hemoglobin beta chains
US8084017B2 (en) 2002-03-07 2011-12-27 Carnegie Mellon University Contrast agents for magnetic resonance imaging and methods related thereto
US7998704B2 (en) * 2002-03-07 2011-08-16 Carnegie Mellon University Methods for magnetic resonance imaging
CA2485363C (en) * 2002-05-10 2014-10-28 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
FI20030615A0 (fi) * 2003-04-24 2003-04-24 Marko Virta Nanopartikkeli bioaffiniteettimäärityksiin
WO2004088313A1 (en) * 2003-04-02 2004-10-14 Tero Soukka Nanoparticle for bioaffinity assays
RU2007124731A (ru) * 2004-12-02 2009-01-10 Ксир (Za) Грамположительные бактерии, продуцирующие рекомбинантные белки
CN101501062B (zh) * 2005-07-26 2012-07-18 康哲医药研究(深圳)有限公司 新型生物活性肽及其新用途
ATE491022T1 (de) * 2005-10-18 2010-12-15 Nat Jewish Health Konditionell immortalisierte adulte langzeit- stammzellen und verfahren zur herstellung und verwendung von solchen zellen
KR100772491B1 (ko) 2005-10-31 2007-11-01 고려대학교 산학협력단 ＤｎａＫ와 고친화력을 가지는 모티브를 포함하는 주형단백질과 탐침 단백질이 융합된 단백질 나노입자
GB0621894D0 (en) * 2006-11-02 2006-12-13 Iti Scotland Ltd Magnetic recognition system
US20120009624A1 (en) * 2006-12-04 2012-01-12 Jens Sommer-Knudsen Protein particles
WO2008124483A1 (en) * 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CN102115746B (zh) * 2009-12-30 2013-06-05 中国科学院地质与地球物理研究所 一种单分散性磁性人铁蛋白的制备方法
CN105399833B (zh) 2010-01-04 2019-09-06 Kj 生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
US9718862B2 (en) 2010-10-06 2017-08-01 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
EP2762488B1 (de) * 2011-09-30 2018-11-21 Korea University Research and Business Foundation, Sejong Campus Peptid zur synthese von kieselsäure und verwendung davon
KR101477123B1 (ko) * 2011-10-12 2014-12-29 한국생명공학연구원 항체결합 펩타이드-페리틴 융합단백질 및 이의 용도
WO2013152274A1 (en) 2012-04-05 2013-10-10 University Of Washington Through Its Center For Commercialization Epitope- scaffold immunogens against respiratory syncytial virusm (rsv)
US20150098966A1 (en) 2012-05-16 2015-04-09 Kj Biosciences Llc Influenza vaccines
AU2013292330B2 (en) 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2015054639A1 (en) * 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
KR101612095B1 (ko) * 2014-01-16 2016-04-26 한국과학기술연구원 바이오마커의 조기 검출 및 정밀 정량화가 가능한 바이오마커 탐지용 프로브 및 이의 용도
EP4134096A1 (de) 2014-05-27 2023-02-15 The U.S.A. as represented by the Secretary, Department of Health and Human Services Stabilisierte influenza-hämagglutininstammregionstrimere und verwendungen davon
US11202820B2 (en) 2014-09-25 2021-12-21 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
CN105801706B (zh) * 2014-12-31 2019-10-22 深圳先进技术研究院 蝎氯毒素多肽-铁蛋白重链融合蛋白、自组装蛋白质纳米笼及其制备方法和应用
WO2016109792A2 (en) 2014-12-31 2016-07-07 The Usa, As Represented By The Secretary, Detp. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US10420830B2 (en) 2015-01-29 2019-09-24 Agency For Science, Technology And Research Nanocapsules carrying chikungunya-associated peptides
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
WO2017039382A1 (ko) * 2015-09-02 2017-03-09 경북대학교 산학협력단 인간 유래 페리틴 모노머 단편 및 이를 이용한 융합폴리펩티드
US10688175B2 (en) 2015-10-13 2020-06-23 Daniel C. Carter NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
EP3383426A1 (de) * 2015-12-04 2018-10-10 Dana Farber Cancer Institute, Inc. Impfung mit mica/b-alpha-3-domäne zur behandlung von krebs
CN107344969B (zh) * 2016-05-05 2021-03-05 中国科学院武汉病毒研究所 一种纳米流感疫苗及构建方法和应用
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CN106046177B (zh) * 2016-08-19 2020-02-21 北华大学 P-5m-Fc融合蛋白及其表达基因、制备方法和应用
US11338033B2 (en) 2016-09-02 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2018102678A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
WO2018128412A1 (ko) * 2017-01-06 2018-07-12 경북대학교 산학협력단 혈전-표적성 펩타이드, 페리틴 단편 및 혈전 용해성 펩타이드를 포함하는 융합 펩타이드 및 이의 용도
US10538756B2 (en) 2017-03-06 2020-01-21 The Trustees Of Princeton University Disordered protein-based seeds for molecular clustering
CN108976299B (zh) * 2017-06-05 2020-02-14 昆山新蕴达生物科技有限公司 一种改善抗体片段亲和力和体内半衰期的方法
CN107325176B (zh) * 2017-06-16 2020-12-25 神威药业集团有限公司 源于血红蛋白的免疫活性人胎盘多肽
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
CA3095175A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic respiratory syncytial virus polypeptides
JP7614842B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性エプスタインバーウイルスポリペプチド
CA3095174A1 (en) * 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
EP3801601A4 (de) * 2018-06-05 2022-09-28 International AIDS Vaccine Initiative Ferritin-nanopartikel, die ein hiv-trimer aufweisen
US11883485B2 (en) 2018-08-29 2024-01-30 Fred Hutchinson Cancer Center Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 Env using multimerized Env cores
CN109966483B (zh) * 2019-04-08 2021-07-30 中国科学院过程工程研究所 一种基于铁蛋白的多抗原通用流感疫苗及其制备方法和应用
EP3952909A4 (de) 2019-04-08 2023-06-07 Taiga Biotechnologies, Inc. Zusammensetzungen und verfahren zur kryokonservierung von immunzellen
TWI776048B (zh) * 2019-04-25 2022-09-01 財團法人農業科技研究院 預防豬瘟病毒感染之重組蛋白質及含其之組合物及細胞
WO2020215266A1 (zh) * 2019-04-25 2020-10-29 财团法人农业科技研究院 预防猪瘟病毒感染的重组蛋白质及含其的组合物及细胞
SG11202112529WA (en) 2019-05-14 2021-12-30 Taiga Biotechnologies Inc Compositions and methods for treating t cell exhaustion
WO2020243895A1 (zh) * 2019-06-04 2020-12-10 上海鑫湾生物科技有限公司 促进毛发生长和/或再生的疫苗、其制备方法及其应用
AU2020320459A1 (en) * 2019-08-01 2022-03-03 The Governing Council Of The University Of Toronto Multi-valent and multi-specific nanoparticle platforms and methods
CN110478480B (zh) * 2019-08-22 2022-06-24 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 基于铁蛋白纳米颗粒的羊口疮f1l疫苗及其制备方法
WO2021045210A1 (ja) * 2019-09-05 2021-03-11 味の素株式会社 ペプチド内包フェリチン
CN110898219B (zh) * 2019-12-11 2022-01-14 中国科学院生物物理研究所 基于铁蛋白与preS1抗原基因融合表达的疫苗
CN111603555B (zh) * 2020-03-23 2022-10-21 东北农业大学 一种自组装牛副流感病毒3型纳米颗粒样抗原及其应用
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
CN112342207B (zh) * 2020-11-27 2022-09-30 华侨大学 一种低速离心纯化重组木聚糖酶的方法
CN117222656A (zh) * 2021-05-03 2023-12-12 安捷伦科技有限公司 嵌合免疫原和用于制备针对特定表位的多克隆抗体的方法
WO2025076013A1 (en) 2023-10-01 2025-04-10 Vaccine Company, Inc. Engineered middle east respiratory syndrome proteins and related methods
WO2025077347A1 (zh) * 2023-10-13 2025-04-17 江南大学 多聚融合蛋白纳米载体及其应用
CN119320460B (zh) * 2024-12-17 2025-03-14 中国农业科学院生物技术研究所 Bst DNA聚合酶和铁蛋白的融合蛋白及其突变体和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
CA2064069A1 (en) 1989-08-18 1991-02-19 Bruce F. Monzyk Ferritin analogs
US5248589A (en) 1991-02-21 1993-09-28 Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Separation of cells and biological macromolecules by ferritin conjugates
CA2258082A1 (en) * 1996-06-12 1997-12-18 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
CA2485363C (en) * 2002-05-10 2014-10-28 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications

Also Published As

Publication number Publication date
EP1504037B1 (de) 2009-12-30
AU2003228962A1 (en) 2003-11-11
US7097841B2 (en) 2006-08-29
WO2003094849A3 (en) 2004-04-15
AU2003228962A8 (en) 2003-11-11
CN105566497A (zh) 2016-05-11
EP1504037A2 (de) 2005-02-09
CA2485363C (en) 2014-10-28
US20040006001A1 (en) 2004-01-08
EP1504037A4 (de) 2005-06-08
CN1659187A (zh) 2005-08-24
WO2003094849A2 (en) 2003-11-20
US7608268B2 (en) 2009-10-27
CA2485363A1 (en) 2003-11-20
DE60330767D1 (de) 2010-02-11
US20060251679A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
ATE453669T1 (de) Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
ATE360031T1 (de) Chimäre proteine und anwendungen
JP2019013251A5 (de)
MX2020010466A (es) Vectores de virus que evitan anticuerpos.
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
EE200200538A (et) Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
DE60325892D1 (de) Stellungs- und verwendungsverfahren
GEP20105111B (en) Rage fusion proteins and methods of use
DK1767546T3 (da) Angiogenese-inhiberende kimært protein og dets anvendelse
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
ATE350049T1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
MX2009011638A (es) Composiciones basadas en gp5 de prrsv y metodos.
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
DE60335726D1 (de) Chromoprotein und fluoroproteine
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
EA200501711A1 (ru) Семейство секретируемых белков
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
MXPA05009954A (es) Familia de proteinas secretadas.
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties